Moratorium pushes Glenmark to new Indian site for Napo's crofelemer
This article was originally published in Scrip
Executive Summary
A Indian government-imposed temporary moratorium on new projects in Ankleshwar is said to have forced Glenmark to consider an alternative site in Aurangabad for manufacturing the active pharmaceutical ingredient (API) for Napo Pharmaceuticals' anti-secretory gastrointestinal agent, crofelemer. However, the company says that the moratorium is a general one and nothing to do with any of Glenmark's specific processes or plants.